Abstract
Type I interferon (IFN) is critical in our defense against viral infections. Increased type I IFN pathway activation is a genetic risk factor for systemic lupus erythematosus (SLE), and a number of common risk alleles contribute to the high IFN trait. We hypothesized that these common gain-of-function IFN pathway alleles may be associated with protection from mortality in acute COVID-19. We studied patients admitted with acute COVID-19 (756 European-American and 398 African-American ancestry). Ancestral backgrounds were analyzed separately, and mortality after acute COVID-19 was the primary outcome. In European-American ancestry, we found that a haplotype of interferon regulatory factor 5 (IRF5) and alleles of protein kinase cGMP-dependent 1 (PRKG1) were associated with mortality from COVID-19. Interestingly, these were much stronger risk factors in younger patients (OR=29.2 for PRKG1 in ages 45-54). Variants in the IRF7 and IRF8 genes were associated with mortality from COVID-19 in African-American subjects, and these genetic effects were more pronounced in older subjects. Combining genetic information with blood biomarker data such as C-reactive protein, troponin, and D-dimer resulted in significantly improved predictive capacity, and in both ancestral backgrounds the risk genotypes were most relevant in those with positive biomarkers (OR for death between 14 and 111 in high risk genetic/biomarker groups). This study confirms the critical role of the IFN pathway in defense against COVID-19 and viral infections, and supports the idea that some common SLE risk alleles exert protective effects in anti-viral immunity.
Background We find that a number of IFN pathway lupus risk alleles significantly impact mortality following COVID-19 infection. These data support the idea that type I IFN pathway risk alleles for autoimmune disease may persist in high frequency in modern human populations due to a benefit in our defense against viral infections.
Translational Significance We develop multivariate prediction models which combine genetics and known biomarkers of severity to result in greatly improved prediction of mortality in acute COVID-19. The specific associated alleles provide some clues about key points in our defense against COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding sources: Niewold TB: Colton Center for Autoimmunity, National Institutes of Health (AI167271, AR078416, AR065964), the Lupus Research Foundation, and the Lupus Research Alliance. Wampler Muskardin TL: Colton Center of Autoimmunity, Doris Duke Fund to Retain Clinician Scientists, NYU-H+H CTSI (UL1TR001445)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of NYU Langone Health gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding Sources: Niewold TB: Colton Center for Autoimmunity, National Institutes of Health (AI167271, AR078416, AR065964), the Lupus Research Foundation, and the Lupus Research Alliance. Wampler Muskardin TL: Colton Center of Autoimmunity, Doris Duke Fund to Retain Clinician Scientists, NYU-H+H CTSI (UL1TR001445)
Disclosures: TBN has received research grants from EMD Serono, Inc., and has consulted for Thermo Fisher, Progentec, Roivant Sciences, Ventus, Toran, and Inova, all unrelated to the current manuscript.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- IFN
- interferon
- SLE
- systemic lupus erythematosus
- COVID-19
- coronavirus disease 2019
- IRF
- interferon regulatory factor,
- PRKG1
- protein kinase cGMP-dependent 1
- CRP
- C-reactive protein
- STAT4
- signal transducer and activator of transcription 4
- IFIH1
- interferon-induced with helicase c domain 1
- BMI
- body mass index
- SNP
- single nucleotide polymorphism
- NYU
- New York University,
- OR
- odds ratio
